Dr. Hong Zheng 郑虹
Chief Physician, Associate Professor
Department of Gynecologic Oncology, Peking University Cancer Hospital, Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of gynecologic malignancies.
Dr. Zheng earned a medical degree from Beijing Medical University in 1998 and a PhD in obstetrics and gynecology from Peking University in 2003. After completing postdoctoral research at MD Anderson Cancer Center (2005–2007) and working at Peking University First Hospital, Dr. Zheng joined the gynecology department of Peking University Cancer Hospital in 2007.
Professional roles
- Member, Youth Committee of the Gynecologic Oncology Branch, Chinese Medical Association
- Member, Geriatric Oncology Professional Committee, China Geriatrics Society
Name order: in Chinese the family name comes first (Zheng Hong). Papers usually list the name as Hong Zheng or Zheng H.
Selected publications
52 papers on PubMed matched by name and affiliation; 9 as first or senior author since 2016. Most recent first- or senior-author papers:
- BMC Womens Health, 2026 (senior author): Clinicopathological characteristics and prognostic analysis of synchronous endometrioid endometrial and ovarian carcinomas: a retrospective cohort study. PubMed 42169062
- Cancer Sci, 2026 (senior author): Systematic Multiplatform Discovery of Methylation Markers Enables Non-Invasive Early Detection of Endometrial Cancer. PubMed 41793107
- Curr Med Imaging, 2026 (senior author): Non-contrast MRI Radiomics Nomogram for Predicting Recurrence and Progression-free Survival in Cervical Cancer following Concurrent Chemoradiotherapy. PubMed 42515922
- Gynecol Oncol, 2025 (senior author): The prognostic value of tumor-informed minimal residual disease detection using circulating tumor DNA in first-line treatment of ovarian cancer. PubMed 39579602
- BMC Womens Health, 2024 (senior author): Disparities in treatment modalities and survival among older patients with high-grade serous ovarian cancer. PubMed 38326784
- Gynecol Oncol, 2023 (senior author): Circulating T-cell receptor diversity as predictive biomarker for PARP inhibitors maintenance therapy in high grade serous ovarian cancer. PubMed 36442424
- Front Oncol, 2021 (first author): Construction and Validation of a Platinum Sensitivity Predictive Model With Multiple Genomic Variations for Epithelial Ovarian Cancer. PubMed 34604063
- Mol Cancer Ther, 2021 (first author): Real-world Experience of Olaparib Treatment in Patients with Ovarian Cancer: A Chinese Multicenter Study. PubMed 34224363
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion